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Abstract
Juvenile traumatic brain injury (jTBI) is the leading cause of death and disability for children and adolescents worldwide, but there
are no pharmacological treatments available. Aquaporin 4 (AQP4), an astrocytic perivascular protein, is increased after jTBI, and
inhibition of its expression with small interference RNA mitigates edema formation and reduces the number of reactive
astrocytes after jTBI. Due to the physical proximity of AQP4 and gap junctions, coregulation of AQP4 and connexin 43
(Cx43) expressions, and the possibility of water diffusion via gap junctions, we decided to address the potential role of astrocytic
gap junctions in jTBI pathophysiology. We evaluated the role of Cx43 in the spread of the secondary injuries via the astrocyte
network, such as edema formation associated with blood–brain barrier dysfunctions, astrogliosis, and behavioral outcome. We
observed that Cx43 was altered after jTBI with increased expression in the perilesional cortex and in the hippocampus at several
days post injury. In a second set of experiments, cortical injection of small interference RNA against Cx43 decreased Cx43
protein expression, improved motor function recovery, and decreased astrogliosis but did not result in differences in edema
formation as measured via T2-weighted imaging or diffusion-weighted imaging at 1 day or 3 days. Based on our findings, we can
speculate that while decreasing Cx43 has beneficial roles, it likely does not contribute to the spread of edema early after jTBI.
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Introduction
In the United States, the annual incidence of nonmilitary-
related traumatic brain injury (TBI) is approximately
1.7 million, of which 327,000 are hospitalized and
52,000 die (Faul et al., 2010). Juvenile TBI (jTBI),
which is the leading cause of death and disability in chil-
dren and adolescents, is an important concern because
the population group most affected (emergency depart-
ment visit, hospitalization, and death) are those younger
than 5 years, followed by teenagers aged 15 to 19 years
old (Faul et al., 2010). The consequences of jTBI are
divided into primary and secondary injuries. The initial
primary injury results from the direct and immediate bio-
mechanical disruption of the brain tissue. The secondary
injuries are part of the development of pathophysiology
with delayed molecular mechanisms occurring at sites
directly surrounding the impacted site and expanding
toward regions remote from the initial impact site (Pop
and Badaut, 2011; Plesnila, 2016). The primary injury
1CNRS UMR5287, University of Bordeaux, France
2Department of Physiology, Loma Linda University, CA, USA
3Department of Pediatrics, Loma Linda University Medical Center, CA, USA
4Department of Psychiatry and Human Behavior, Alpert Medical School of
Brown University, Providence, RI, USA
5Center for Glial-Neuronal Interactions, Division of Biomedical Sciences,
University of California, Riverside, CA, USA
6Department of Pediatrics, University of California, Irvine, CA, USA
*These authors equally contributed to the work.
Corresponding Author:
Jerome Badaut, CNRS UMR 5287, University of Bordeaux, 146 rue Le´o
Saignat, 33076 Bordeaux cedex, France.
Email: Jerome.badaut@u-bordeaux.fr
ASN Neuro
Volume 11: 1–14
! The Author(s) 2019
DOI: 10.1177/1759091419847090
journals.sagepub.com/home/asn
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.
creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the
original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
can only be lessened by taking preemptive cautions, such
as wearing helmets, so the goal of potential therapeutics
is to minimize the damage caused by the secondary inju-
ries (Morales et al., 2005). The major landmarks of the
secondary injury cascade are blood–brain barrier (BBB)
disruption and edema with cellular swelling (Pop and
Badaut, 2011; Fukuda et al., 2012, 2013). Notably, cere-
bral edema remains the most significant predictor of poor
outcome after injury and accounts for half of the mor-
bidity and mortality after jTBI (Donkin and Vink, 2010;
Fukuda et al., 2012, 2013). However, the molecular and
cellular mechanisms in edema spread are not yet well
understood, and there are no pharmacological treatments
available (Clement et al., 2018).
Although various cell types such as neurons, oligoden-
drocytes, and endothelial cells swell after injury, astro-
cytes are the first cell types to respond to injury.
Astrocytes are known to swell before, and longer than
the other cells (Badaut et al., 2011). In fact, perivascular
astrocyte endfeet can react within minutes after injury
(Grange-Messent et al., 1996; Risher et al., 2009), and
this swelling may spread from the primary injury site to
distant sites, thus being responsible for the secondary
injury cascade. To have a better understanding of this
process, examination of astroglial pathophysiology after
jTBI is required to successfully target these injury cas-
cades, including edema. The expression of aquaporin 4
(AQP4), a water channel present predominantly on the
astrocytes endfeet, has been shown to first decrease and
then increase at 3 days and 7 days after jTBI which coin-
cides with both the peak of edema formation at 3 days
and edema resolution at 7 days (Fukuda et al., 2012).
Early downregulation of AQP4 protein levels using
small interference RNA against AQP4 (siAQP4)
decreased edema development after jTBI with behavioral
improvements both during the acute and chronic phases
of injury (Fukuda et al., 2013), suggesting an important
role for astrocytic AQP4 in water movements during
edema. Importantly, astrocytes are organized in a net-
work where they communicate through specialized chan-
nels called gap junctions (Giaume and McCarthy, 1996).
The astrocytic network has been proposed to be involved
in various brain homeostatic functions, in particular
siphoning the excess of potassium ions (Kþ) at distance
of the site of activation of neurons (Niermann et al.,
2001). Very interestingly, the astrocytic AQP4 has been
also proposed to be involved in the Kþ clearance (Binder
et al., 2004, 2006). In addition to the physical relationship
between water channels and gap junctions, connexin
43 (Cx43) expression has been linked to the level of
expression of AQP4 via coregulation by miRNA
(Jullienne et al., 2018). It is very likely that the extent
of the edema in the brain tissue during the development
of secondary injury after jTBI involves gap junctions
(Figure 1(A)).
Astrocytic gap junctions form connections between
neighboring astrocytes, allowing the flow of various mole-
cules and water, and the proteins that constitute these gap
junctions are the connexins (Giaume et al., 2010). Among
the connexins, connexin 43 (Cx43) and connexin 30 (Cx30)
are predominantly expressed in astrocytes (Rash et al.,
2001; Giaume et al., 2010). Six connexin proteins form a
connexon, which is a hemichannel, and when a hemichan-
nel from one cell attaches with another hemichannel of an
adjacent cell, a gap junction is established. Therefore, 12
connexins constitute one gap junction (Giaume et al.,
2010). Connexin hemichannels have an aqueous pore
that selectively permits flow of small endogenous molecules
such as second messengers, amino acids, nucleotides, small
peptides, and also water (Wallraff et al., 2006; Giaume
et al., 2010; Herve and Derangeon, 2013). The hypothe-
sized spread of detrimental factors and toxic metabolites
such as sodium and calcium ions, apoptotic factors, lyso-
phospholipids, cyclic adenosine monophosphate, and ino-
sitol triphosphate from the primary injury site to more
distant sites mediated by gap junctions is referred to as
“bystander effect” (Andrade-Rozental et al., paper 2000;
Perez Velazquez et al., 2003). Several studies have shown
increased astrocytic connexin expression in affected brain
regions after acute injuries such as stroke, TBI, spinal cord
injury, and retinal injury (Chew et al., 2010). However, no
studies have characterized the levels of the connexins form-
ing astroglial gap junctions after jTBI and their association
with edema spread and astrogliosis.
Materials and Methods
General Experimental Setup
For this study, two independent sets of rats were used: in
the first set of animals, the changes in the astrocytic net-
work connexin proteins (Cx43, Cx30) and the astrocytic
activation marker glial fibrillary acidic protein (GFAP)
levels were measured over time after jTBI; in the second
set, we evaluated the effect of small interference RNA
against Cx43 (siCx43) injection after jTBI on astrocytic
markers (Cx43, GFAP, AQP4), neuronal death (with
neuronal nuclei [NeuN] marker), and BBB permeability
(with immunoglobulin G [IgG]). Edema was assessed
using magnetic resonance imaging (MRI), and functional
outcome was evaluated with behavior/motor tests.
Animal Care
All animal care and experiments were conducted according
to the Guidelines for Care and Use of Experimental Animals
approved by Loma Linda University. All protocols and
procedures were in compliance with the U.S. Department
of Health and Human Services Guide and were approved by
the Institutional Animal Care and Use Committee of Loma
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Linda University. Postnatal 17-day-old Sprague Dawley
male rat pups were housed in a temperature-controlled
(22C–25C) animal facility on a 12-hr light/dark cycle
with standard lab chow and water ad libitum.
siRNA Preparation
An in vivo Cx43 silencing protocol was adapted from pre-
vious studies (Badaut et al., 2011). Briefly, SMART-poolVR
containing 4 siRNA-duplexes against Cx43 (400 ng,
siCx34, Dharmacon Research, Horizon Discovery,
Cambridge, United Kingdom) and nontargeted siRNA
(siGLO RISC-free-control-siRNA, Dharmacon Research,
Horizon Discovery, Cambridge, United Kingdom) were
mixed with INTERFERinVR (Polyplus-transfection,
Illkirch, France) diluted in a saline solution (0.9%) contain-
ing 5% glucose for a final volume of 5 lL and incubated on
ice for 20 minutes before injection.
Controlled Cortical Impact and siRNA Injection
Controlled cortical impact (CCI) was carried out on
postnatal 17-day-old rat pups as previously described
(Ajao et al., 2012; Fukuda et al., 2012, 2013). Rats
were anesthetized with isoflurane and placed in a stereo-
taxic apparatus (David Kopf Instrument, Tujunga, CA,
USA). A 5mm diameter craniotomy over the right hemi-
sphere 3 mm posterior from bregma and 4 mm lateral to
midline was performed. Animals were subjected to CCI
using an electromagnetic impactor with a 2.7mm round
Figure 1. (A) Schematic representation of the working hypothesis and the site of siCx43 injection (A1) gap junctions composed of Cx43
and Cx30 are involved in the spread of edema after TBI. siCx43 inhibits overexpression of Cx43 and limits the edema spread. (A2) Red
arrow indicates the siCx43 injection site in the perilesional cortex, and white arrows point ventricle changes. (B) Representative GFAP
immunofluorescence confocal images in the perilesional cortex at 3 days (B1, B2) and 60 days after injury (B3, B4), scale bar¼ 40 lm. (C)
GFAP staining quantification in the perilesional cortex showed increased GFAP immunoreactivity at 1 day, 3 days, 7 days, and 60 days after
jTBI when compared with sham. (D) GFAP immunoreactivity in the ipsilateral hippocampus (CA1) showed a significant increase only at 1
day. Scale bar¼ 40 lm (*p< .05).
AQP4¼ aquaporin 4; Cx43¼ connexin 43; Cx30¼ connexin 30; GFAP¼ glial fibrillary acidic protein; jTBI¼ juvenile traumatic brain
injury; ROI¼ region of interest; siCx43¼ small interference RNA against Cx43.
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tip set to impact with a velocity of 6 m/s and a depth of
1.5 mm below the cortical surface (Leica, Richmond, IL,
USA). Sham animals received the craniotomy, but with-
out the cortical impact. The craniotomy did not cause
damage to the dura mater, which was intact in both the
jTBI and sham groups. After CCI, none of the animals
had major bleeding or cortical tissue herniation.
siRNA administration was performed as previously
described (Fukuda et al., 2013). Injection of siRNA was
performed 10 minutes after the injury lateral to the site of
the impact using a 30-gauge needle on a Hamilton syringe
(3mm posterior to bregma, 6 mm lateral to midline, and
1.0 mm below cortical surface). The syringe was attached
to a nanoinjector (Leica Microsystems, Wetzlar,
Germany), and 4 lL of either siCx43 or siGLO was
administered at a rate of 0.5 lL/min. After suturing, all
pups were placed on a warm heating pad for recovery
before being returned to their dams. A second siRNA
injection was repeated 2 days after the CCI in all pups
that received siRNA using the same injection protocol.
Magnetic Resonance Imaging
MRI was performed at 1 day and 3 days after jTBI to
monitor the process of edema formation and to observe
water content and water mobility at the peak of edema in
this model (Fukuda et al., 2012, 2013). Pups were lightly
anesthetized using isoflurane (1.0%) and imaged on a
Bruker Avance 11.7 T (Bruker Biospin, Billerica, MA,
USA; Fukuda et al., 2013). Two imaging data sets were
acquired: (a) a 10 echo T2-weighted (T2WI) and (b) a
diffusion-weighted imaging (DWI) sequence in which
each sequence collected 20 coronal slices (1 mm thickness
and interleaved by 1 mm). The 11.7T T2WI sequence had
the following parameters: TR/TE¼ 2357.9/10.2ms,
matrix¼ 128 128, field of view¼ 2 cm, and 2 averages.
The DWI sequence had the following parameters:
TR/TE¼ 1096.5/50ms, two b values (116.96,
1044.42 s/mm2), matrix¼ 128 128, field of view¼ 2 cm,
and 2 averages.
Region of Interest and Volumetric Analysis
T2 relaxation values (ms) and apparent diffusion coeffi-
cient (ADC) values were quantified using previously pub-
lished standard protocols (Badaut et al., 2011). Regions
of interest (ROIs) were placed on the imaging section
with the maximally detected injury using Cheshire
(Parexel International Corp., Waltham, MA, USA).
Perilesional cortex and ipsilateral hippocampus were
delineated on T2WI images and overlaid onto corre-
sponding T2 and ADC maps (Figure 1(A2)). The
mean, standard deviation, and area for each ROI
were extracted.
Behavioral Testing
Foot-fault and rotarod testing was performed at 1 day
and 3 days after injury in both the siCx43 and control
(siGLO) group. The foot-fault test evaluated sensorimo-
tor coordination and proprioception while the rotarod
test tested sensorimotor coordination and balance as pre-
viously reported (Ajao et al., 2012). All tests at each time
point were carried out on siGLO- and siCx43-treated rats
within a 3-hour morning time-block (8–11 a.m.). siGLO-
and siCx43-treated rats were interleaved in the testing
sequence. To further control for potential confounds,
the same tests were administered in the same order at
all of the time points, by the same investigators blinded
to the experimental groups.
Foot-fault testing was carried out on an elevated plat-
form (50 cm 155 cm, ClosetMaid, Ocala, FL, USA)
with parallel wire bars 1.5 cm apart and raised 100 cm
above the floor. Rats were placed in the middle of the
platform to freely roam around. When a rodent’s paw
(fore- or hindlimb) slipped completely through the wire
mesh, it was considered as an individual fault. The aver-
age foot-fault score was calculated from the total number
of faults from two 60 seconds trials.
Rotarod evaluation (SD Instruments, San Diego, CA,
USA) was performed with a rotating 7-cm wide spindle
with continuous speed (20 rpm) to evaluate performance
during two trials per speed. Latency to fall was the out-
come measure of motor coordination and balance. The
maximum time spent on the test was 60 seconds, if the rat
did not fall, at which point the rotation was halted and
the rat was taken off of the spindle. The average time
spent on the rotarod from the two trials was calculated
and expressed in total time (seconds) for two trials.
Immunohistochemistry and Image Analysis
For the immunohistochemistry experiments, the animals
were transcardially perfused at the respective time point
with 4% paraformaldehyde after which brains were
extracted and put in 30% sucrose for 48 hours, then
stored in –22C. Coronal sections were cut at 40 lm
thickness at –22C on a cryostat (Leica Biosystems,
Wetzlar, Germany) and then mounted on slides for sub-
sequent immunohistochemical analysis (Hirt et al., 2009;
Badaut et al., 2011).
The primary antibodies used for immunohistochemis-
try were rabbit polyclonal antibody for Cx43 (1:100,
Abcam, Cambridge, MA, USA; RRID:AB_297976),
rabbit polyclonal antibody for Cx30 (1:100, Abcam;
RRID:AB_10862289), chicken polyclonal antibody
against GFAP (1:1000, Millipore, Billerica, MA, USA;
RRID:AB_177521), rabbit polyclonal antibody against
AQP4 (1:200, Sigma-Aldrich, St. Louis, MO, USA;
RRID:AB_1844967), and rabbit polyclonal against
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NeuN (1:500, Abcam; RRID:AB_2744676).
The secondary antibodies used were InfraRed Dye
(IRDye) 800-conjugated affinity-purified donkey-anti-
rabbit IgG (1:1000, Rockland, Gilbertsville, PA, USA;
RRID:AB_1057615), IRDye 680-conjugated affinity-
purified goat-anti-chicken IgG (1:1000, Rockland;
RRID:AB_10705059), Alexa 594-conjugated affinity-
purified goat anti-rabbit IgG (1:1000, Invitrogen,
Carlsbad, CA, USA; RRID:AB_2556545), Alexa 488-
conjugated affinity-purified goat anti-rabbit IgG
(1:1000, Invitrogen; RRID:AB_2556544), Alexa 568-con-
jugated affinity-purified goat anti-chicken IgG (1:1000,
Invitrogen; RRID:AB_2534098), and Alexa 488-conju-
gated affinity-purified goat anti-chicken IgG (1:1000,
Invitrogen; RRID:AB_2534096).
For immunohistochemistry, sections were washed with
phosphate-buffered saline (PBS), blocked with 1% bovine
serum albumin (BSA) in PBS, incubated with the respec-
tive primary antibodies in PBS containing 0.1% Triton X-
100 and 1% BSA overnight, then incubated for 2 hours at
room temperature with affinity-purified secondary anti-
bodies conjugated to the desired wavelength in PBS con-
taining 0.1% Triton X-100 and 1% BSA. After washing,
brain sections were scanned on an infrared (IR) scanner
(Odyssey, Lincoln, NE, USA) to quantify fluorescence for
the different ROIs as previously described (Badaut et al.,
2011) or imaged under a confocal laser microscope (Zeiss,
Oberkochen, Germany) or epifluorescence microscope
(Leica Microsystems, Wetzlar, Germany). For sections
that were imaged under epifluorescence or confocal
microscopy, sections on glass slides were coverslipped
with antifading medium VectaShield containing 4’,6-dia-
midino-2-phenylindole (Vector, Vector Laboratories,
Burlingame, CA, USA).
All image acquisition parameters for the same proteins
were kept constant for all of the animals for analysis and
visualization purposes, and all analyses were carried out
in a nonbiased, blinded manner. Analysis of Cx43,
GFAP, and NeuN used previously described methods
(Fukuda et al., 2013). The slides with the previously men-
tioned primary antibodies with the secondary antibodies
conjugated to the IR wavelength (680 or 800 nm) were
scanned on an IR scanner (Odyssey), and images were
saved with a resolution of 21 lm per pixel. Identical cir-
cular ROIs were drawn in the perilesional cortex and in
the ipsilateral CA1 at three different bregma levels (–1.40
mm, –2.56 mm, and –3.80 mm): the bregma level where
lesion area was largest, one slice anterior and one poste-
rior. The average fluorescence of these ROIs was calcu-
lated to show immunoreactivity of each of the protein
and between groups. 4 consecutive images with 20mag-
nification were taken in the ipsilateral cortex around the
lesion site, at 2 different bregma levels (2.56 mm and
–3.80 mm). The average fluorescence intensity and the
area of staining were measured after processing the
images with the Frangi vesselness plugin followed by
the Renuy entropy filter in ImageJ (Bethesda, MD,
USA) to isolate the vascular staining from the back-
ground. Negative control staining where the primary
antibody or secondary antibody was omitted showed
no detectable labeling.
For IgG extravasation immunohistochemistry, sections
were washed with PBS, blocked with 1% BSA in PBS, then
incubated for 2 hours at room temperature with IRDye
800-conjugated affinity-purified goat-anti-rat IgG (1:500,
Rockland; RRID:AB_1961673) in PBS containing 0.1%
Triton X-100 and 1% BSA. After washing, sections were
scanned on an IR scanner (Odyssey) to measure the area of
extravasation divided by the total brain area per ROI.
Western Blot
At 3 days and 7 days, brains were freshly extracted from
another set of sham and jTBI animals, and the cortical
tissue adjacent to the site of impact was collected and
frozen for Western blot analysis as previously published
(Fukuda et al., 2012). Tissues were placed in a tube with
radioimmunoprecipitation assay buffer with protease
inhibitor cocktail (Roche, Basel, Switzerland) and soni-
cated for 30 seconds and stored at –20C. These samples
were then analyzed for total protein concentration by
bicinchoninic acid assay (Pierce Biotechnology Inc.,
Rockford, IL, USA). 10 mg of protein were then sub-
jected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis on a 4% to 12% gel (NuPAGE, Invitrogen).
After the electrophoresis, proteins were transferred to a
polyvinylidene fluoride membrane (PerkinElmer,
Germany). The membrane was incubated with a rabbit
polyclonal antibody against Cx43 (1:1000, Abcam;
RRID:AB_297976) and a monoclonal antibody against
tubulin (1:25,000, Sigma, Switzerland; RRID:
AB_477579) in Odyssey blocking buffer (LI-COR,
Bioscience, Germany) for 2 hours at room temperature.
After washing in PBS for 3 10 min, the membrane was
incubated with two fluorescence-coupled secondary anti-
bodies (1:10,000, anti-rabbit Alexa-Fluor-680 nm,
Molecular Probes, Eugene, OR, USA; RRID:
AB_2535736 and anti-mouse IRDye-800-nm, Roche,
Germany; RRID:AB_621842) for 2 hours at room tem-
perature. After 3 10 minutes washes in PBS, the degree
of fluorescence was measured using an IR scanner
(Odyssey, LI-COR, Germany) as previously published
(Fukuda et al., 2012). The fluorescence value for Cx43
was normalized to tubulin and compared between jTBI
and sham at each time point.
Statistics
One-way analysis of variance (ANOVA) was used for the
immunohistochemistry and Western blot analysis to
Ichkova et al. 5
compare the means between the sham and jTBI group at
each time point. One-way ANOVA was used for immu-
nohistochemistry analysis to compare the mean between
siGLO and siCx43 group as well. Two-way repeated
measures ANOVA with a post hoc Bonferroni test was
used for the behavior and MRI data. A p value less than
.05 was considered to be statistically significant. All data
in the article are presented as mean standard error of
the mean. For the first set of experiments, the number of
animals was n¼ 24 for sham and n¼ 24 for jTBI animals.
For the second set of experiments, the number of animals
for all tests was n¼ 5 for the siGLO-treated group and
n¼ 7 for siCx43-treated rats.
Results
Chronic Astrogliosis After jTBI
The extent of astrogliosis after jTBI was studied via
GFAP immunoreactivity, a protein found in the astro-
cyte cytoskeleton of activated astrocytes (Sofroniew and
Vinters, 2010; Figure 1(B)). GFAP immunofluorescence
intensity was significantly increased in the perilesional
cortex (Figure 1(B2) and (B4)) in the jTBI group com-
pared with the age-matched control group at 1 day, 3
days, 7 days, and 60 days after injury (Figure 1(C)).
Unlike the perilesional cortex in which significant
increases in astrogliosis were observed at all time
points, the ipsilateral hippocampus only had a significant
increase (p< .05) at 1 day (Figure 1(D)).
Chronic Increase of Cx43 Expression Associated With
Astrogliosis After jTBI
Cx43 staining was observed around the blood vessels
with a dotted pattern (Figure 2(A1) and (A3)) in the
sham groups at 3 days and 60 days. Cx43 staining was
increased in the jTBI rats around blood vessels and
within brain parenchyma (Figure 2(A2) and (A4)).
Quantification of Cx43 changes at 1 day, 3 days, 7
days, and 60 days post-jTBI using the same ROI used
for GFAP immunoreactivity quantification was under-
taken. At 1 day, there was no significant difference in
the mean immunofluorescence values between the
groups (Figure 2(B)), although a 40% decrease in Cx43
immunofluorescence was observed after jTBI (p< .125).
However, during the edema formation period, which
lasts from 3 days to 7 days after injury in this model
(Fukuda et al., 2012), there was significant increase in
the Cx43 immunofluorescence levels in the perilesional
cortex by 53% at 3 days and 47% at 7 days in the jTBI
group compared with age-matched sham-operated ani-
mals (Figure 2(B), p< .05). Furthermore, the increase
of the Cx43 immunoreactivity was still observed at 60
days post-injury (Figure 2(B), p< .05). Similar increases
at 3 days were observed (p< .05) in the ipsilateral hippo-
campus located directly under the site of the impact,
when compared with age-matched sham-operated ani-
mals (Figure 2(C)). This early Cx43 increase was not
sustained after 7 days and 60 days in the hippocampus.
No differences were observed between groups in the con-
tralateral cortex and hippocampus (data not shown).
Immunohistochemical quantification was confirmed
by Western blot analysis at 3 days and 7 days (Figure 2
(D)). The Cx43 Western blot showed a higher intensity in
the jTBI group compared with sham animals at 43 kDa.
The intensity of Cx43 staining was normalized to the
b-tubulin, which was used as a housekeeping protein
(Figure 2(D) and (E)). Quantification revealed a signifi-
cant increase, with 30% increase at 3 days and 200%
increase at 7 days (Figure 2(E)).
Even though the focus of the study was on Cx43, to
assess the overall changes in astrocytic connexins, Cx30
protein changes were also evaluated using IR immuno-
histochemistry at 1 day, 3 days, 7 days, and 60 days
post-jTBI. At 1 day and 3 days, a significant increase
was observed in Cx30 immunoreactivity in the perile-
sional cortex in the injured animals compared with age-
matched sham-operated control animals (Supplementary
Figure 1(A) and (B), p< .05). However, no significant
difference between the groups was observed in the perile-
sional cortex at 7 days and 60 days (Supplementary
Figure 1(B)). In the ipsilateral hippocampus located
under the site of the impact, a significant increase in
Cx30 immunoreactivity was observed at 1 day (p< .05)
when compared with age-matched sham-operated ani-
mals but not at the other time points (Supplementary
Figure 1(C)).
siCx43 Injection Reduces Cx43 Expression Acutely
After Injury
In our results, we found that in the perilesional cortex of
jTBI animals, there was an initial decrease in Cx43 pro-
tein expression followed by a sustained increase at long
term (Figure 2). This is in contrast to the Cx30 expression
results where only an initial increase in protein expression
in the perilesional cortex was observed (Supplementary
Figure 1). Interestingly, the pattern of Cx43 changes in
the first week is similar to the one described for AQP4
(Fukuda et al., 2012), and our previous study using the
same jTBI model and siAQP4 showed beneficial effect of
the treatment on the outcome after injury (Fukuda et al.,
2013). We therefore decided to study the functional con-
sequences of decreasing Cx43 expression using the
siRNA approach after jTBI on the edema formation,
astrogliosis, neuronal cell death, and functional recovery.
For this purpose, siCx43 was injected in the lesion site
after injury as previously described for siAQP4 (Fukuda
et al., 2013; Jullienne et al., 2018). Protein changes were
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measured using IR immunohistochemistry at 3 days post-
jTBI to evaluate whether siCx43 was effective in decreas-
ing Cx43 expression. siCx43 induced a significantly lower
level of Cx43 expression compared with the siGLO con-
trol group at 3 days after the injury (19% decrease) in the
perilesional cortex (Figure 3(A) to (C)), but no significant
difference was observed in the ipsilateral hippocampus
(Figure 3(D)) in accordance with previous reports
(Jullienne et al., 2018).
siCx43 Injection Resulted in Improved Behavioral
Outcomes With No Effect on Edema After jTBI
siCx43 treatment had beneficial effects on the motor
behavior after jTBI. The siCx43-treated jTBI group had
fewer foot-faults than the control siGLO-treated pups at
1 day and 3 days after injury—24% and 36% respective-
ly, F(1, 10)¼9.48, p< .01 (Figure 4(A)). There was a time
effect with a significant decrease of foot-faults between
1 day and 3 days, F(1, 10)¼26.08, p< .0005. siCx43 ani-
mals remained on the rotarod longer than siGLO control
animals, but this difference was not statistically signifi-
cant, F(1, 10)¼ 1.38, p¼ .26 (Figure 4(B)). However,
there was a significant increase of time spent on rotarod
from 1 day to 3 days, F(1, 10)¼15.26, p< .003.
Importantly, siCx43 injection in sham mice did not
have any effect on the motor behavior for either foot
faults (Supplementary Figure 2(A)) or time spent on
the rotarod (Supplementary Figure 2(B)) compared
with siGLO-treated sham animals.
MRI was used to obtain T2 and ADC values in the
perilesional cortex and ipsilateral hippocampus at 1 day
and 3 days in both siCx43 and siGLO groups (n¼ 5
siGLO and n¼ 7 siCx43 animals). There were no signif-
icant differences in T2 values between the siGLO and the
siCx43 group (siGLO [1 day: 116.58 6.82ms; 3 days:
93.54 3.47ms] and siCx43 [1 day: 107.75 7.84ms; 3
days: 101.26 7.85ms]) in the perilesional cortex,
Figure 2. (A) Representative Cx43 immunofluorescence confocal images in the perilesional cortex at 3 days (A1, A2) and 60 days after
injury (A3, A4), scale bar¼ 40 lm. (B) Cx43 staining quantification in the perilesional cortex showed significantly increased Cx43
immunoreactivity at 3 days, 7 days, and 60 days after jTBI when compared with shams. (C) Cx43 immunoreactivity in the ipsilateral
hippocampus (CA1) showed a significant increase at 3 days (*p< .05). (D) Western blot of Cx43 at 3 days and 7 days shows a distinct band
of Cx43 at 43kDa. (E) Western blot quantification shows a significantly higher expression of Cx43 in the perilesional cortex at both 3 days
and 7 days in jTBI compared with shams. Scale bar¼ 40 lm (*p< .05).
jTBI¼ juvenile traumatic brain injury; Cx43¼ connexin 43; kDa¼ kilo Dalton.
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F(1, 0)¼0.003, p¼ .96 (Figure 5(A)). There was time
effect with decreased edema at 3 days, F(1, 0)¼ 12.24,
p¼ .01. Similarly, no significant differences were
observed between siGLO (1 day: 121.53 7.45 ms; 3
days: 99.29 3.01 ms) and siCx43 (1 day: 114.66 8.47
ms; 3 days: 109.45 7.45 ms) in the ipsilateral hippocam-
pus, F(1, 0)¼ 0.04, p¼ .85 (Figure 6(B)). There was time
effect also in the ipsilateral hippocampus with decreased
edema at 3 days, F(1, 0)¼ 10.55, p¼ .01. There was no
Figure 3. (A, B) Confocal images of Cx43 immunofluorescence
staining in the perilesional cortex after siGLO (A) and siCx43
injection (B). (C) Cx43 immunoreactivity was significantly
decreased after siCx43 compared with siGLO-treated rats in the
perilesional cortex (*p< .05). (D) The expression of Cx43 in the
ipsilateral hippocampus was not changed after siCx43 injection.
Scale bar¼ 40 lm.
Cx43¼ connexin 43; DAPI¼ 4’,6-diamidino-2-phenylindole;
IR¼ infrared; siCx43¼ small interference RNA against Cx43.
Figure 4. (A) siCx43-treated pups had better functional out-
comes as revealed by the foot-fault test. siCx43 group had signif-
icantly fewer foot faults than siGLO-treated animals at 1 day (24%)
and 33 days (36%) after jTBI (*p< .05). (B) However, siCx43 ani-
mals’ performance on the rotarod did not significantly differ with
that of siGLO at either 1 day or 3 days.
siCx43¼ small interference RNA against Cx43.
Figure 5. (A) T2-weighted and diffusion-weighted imaging (DWI)
of siGLO and siCx43 rats revealed no overt visual differences
between the groups. The T2 and DW representative images for
each treatment group are from the same rat. The DW image is the
weighted image (b¼ 1000) and no diffusion differences are appar-
ent between the two groups (*¼TBI site). The extent of edema
formation was assessed via MRI using T2 (water content) and ADC
(water mobility). T2 values were not significantly different between
siCx43 and siGLO pups within the (B) perilesional cortex or (C)
ipsilateral hippocampus at either 1 day or 3 days. The ADC value
did not significantly differ between siCx43 and siGLO pups within
the (D) perilesional cortex or (E) ipsilateral hippocampus at 1 day
or 3 days.
siCx43¼ small interference RNA against Cx43; DWI¼ diffusion-
weighted imaging; ADC¼ apparent diffusion coefficient.
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interaction of time and treatment for the T2 values in the
perilesional cortex or the ipsilateral hippocampus.
ADC values also did not exhibit significant differences
between the siGLO and the siCx43 group in the perile-
sional cortex, F(1, 0)¼1.29, p¼ .28 (Figure 5(C)).
Similarly, no significant difference was observed in the
ipsilateral hippocampus between siGLO and siCx43, F
(1, 0)¼0.93, p¼ .36 (Figure 5(D)). There was no time
effect or significant interaction of the time and treatment
for the ADC values at any of the time points.
siCx43 Injection Alters GFAP Expression With No
Direct Neuroprotective Effect
Because we did not observe any changes in the edema
formation between the siCx43- and siGLO-treated ani-
mals, AQP4 expression in the perilesional cortex at 3
days post-jTBI was examined (Supplementary Figure 3).
AQP4 expression was not different (siGLO: 1719 151.0
A.U., siCx43: 1715 124.0 A.U.) between the groups.
Previously, it has been shown that GFAP immunore-
activity was decreased after ischemia in Cx43 knockout
mice and after blocking Cx43 in a TBI model (Nakase
et al., 2003; Wu et al., 2013). We investigated in our
model of jTBI the effects of siCx43 on astrogliosis after
jTBI. In non-jTBI animals, siCx43 injection had no effect
on the GFAP staining compared with the siGLO-injected
rats (Jullienne et al., 2018). However, we found a 17%
decrease in GFAP immunofluorescence in the perile-
sional cortex of siCx43-treated rat pups compared with
siGLO controls (p< .05, Figure 6(A) and (B)).
Because astroglial connexins have been hypothesized
to play a role in BBB permeability (Ezan et al., 2012), we
investigated BBB disruption using IgG immunohisto-
chemistry. At 3 days, there were no significant differences
in the extent of IgG extravasation between siCx43
(18.92%) and siGLO controls (18.40%; Figure 6(C)
and (D)). Thus, there were no differences in the extent
of BBB permeability after jTBI between siCx43-treated
and siGLO animals.
Finally, we investigated the effects of siCx43 on neu-
ronal survival. NeuN immunoreactivity in the perile-
sional cortex was not altered between groups (p> .05,
Figure 6. (A) GFAP immunofluorescence. (B) GFAP quantification in the perilesional cortex showed significant decreases in siCx43
compared with siGLO animals. (C) The extent of IgG extravasation (area of extravasation in the cortex divided by the total brain area) was
not significantly different between siGLO and siCx43 animals (D), signifying no differences in BBB disruption/permeability (*p< .05). (E)
NeuN immunofluorescence as well as quantification within the perilesional cortex showed no differences between siGLO- and siCx43-
treated animals (F). Scale bar¼ 1 mm (*p< .05).
siCx43¼ small interference RNA against Cx43; GFAP¼ glial fibrillary acidic protein; IgG¼ immunoglobulin G; NeuN¼ neuronal nuclei.
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Figure 6(E) and (F)). Overall, the benefits observed on
the motor functions were not supported by decreased
neuronal cell death but a change in the astrocyt-
ic phenotype.
Discussion
This is the first report to characterize the modifications in
Cx43 protein expression after jTBI and the first to assess
the effect of siCx43 on edema and astrogliosis in jTBI.
Our novel findings revealed that Cx43 protein levels were
increased in the perilesional cortex and ipsilateral CA1
after jTBI. GFAP, as a measure of astrogliosis after jTBI,
was also increased up to 60 days after jTBI. Treatment
with siCx43 injection after jTBI resulted in improved
behavioral outcomes and decreased astrogliosis that
were associated with decreased Cx43 protein levels at 3
days postinjury. Therefore, the motor function improve-
ment was not related to neuronal survival but rather to
the extent of astrogliosis.
Changes Seen in Astrocytic Connexins After jTBI:
Relation to Edema?
The term astrocyte network (Giaume et al., 2010) is fre-
quently used to describe the organization of astrocytes in
which individual astrocytes are interconnected through
gap junctions composed of connexin proteins: predomi-
nantly Cx43 and also Cx30, which facilitate intercellular
communication (Seifert et al., 2006; Giaume et al., 2010).
Astrocytes and their networks are essential for normal
brain function, and disruption of this network by TBI
leads to pathological cascades such as excitotoxicity, apo-
ptosis, neuroinflammation, and edema (Sofroniew and
Vinters, 2010; Fukuda and Badaut, 2012).
In the brain, the main astrocytic gap junction forming
proteins are Cx43 and Cx30 (Nagy et al., 2004). Cx43 and
Cx30 stainings have been reported in perivascular astro-
cyte endfeet (Figure 2(A), Supplementary Figure 1;
Jullienne et al., 2018). Although Cx43 and Cx30 are
both the main astrocytic connexin proteins, especially
in perivascular endfeet, the pattern of change was differ-
ent between the two proteins, where Cx30 was increased
acutely after injury (Supplementary Figure 1(A) and (B)),
but Cx43 was decreased initially but then upregulated
chronically. Cx43 expression after jTBI was similar to
the expression of astrocytic AQP4 in this jTBI model
(Fukuda et al., 2012), and for that reason, we hypothe-
sized that Cx43 and AQP4 might have a common role in
the process of post-traumatic edema. Interestingly, Cx43
expression was not changed during the edema formation
phase at 1 day after jTBI, but both AQP4 and Cx43 were
increased during the peak edema phase (3 days) and
during the edema resolution phase (7 days; Fukuda
et al., 2012). Thus, acutely, the expression profile of
Cx43 follows that of AQP4 in support of recent work
showing that decreased AQP4 is followed by a decrease
in Cx43 expression after silencing AQP4 (siRNA;
Jullienne et al., 2018). However, we observed that Cx43
was increased even at 60 days after jTBI, whereas AQP4
was not. This may signify that AQP4 and Cx43 may have
a common functional role during the acute period after
injury but diverge in expression levels after jTBI.
Accordingly, both in vivo and in astrocyte cell cultures,
AQP4 downregulation led to decreased expression of
Cx43 (Jullienne et al., 2018), and in a transgenic mice
lacking Cx43 and Cx30, decreased expression of AQP4
was also observed (Ezan et al., 2012). Thus, Cx43 follows
the pattern of AQP4 and may contribute to edema reso-
lution at 7 days after injury as speculated previously
(Fukuda et al., 2012).
Increased connexin expression after injury has been
proposed to be detrimental in several studies of different
brain pathologies (Chew et al., 2010), but others have
speculated them to be beneficial with no universal con-
sensus (Farahani et al., 2005; Wallraff et al., 2006;
Zweckberger and Plesnila, 2009). In an adult model of
TBI using a lateral fluid percussion injury in adult rats, a
similar pattern of Cx43 immunoreactivity was reported
as in our model of jTBI, wherein an initial reduction was
followed by increases in the hippocampus and the cortex
(Ohsumi et al., 2006). However, it is interesting to note
that the acute reduction was observed at 6 hours and
then increased at 24 hours (Ohsumi et al., 2006). This
apparent shift in the Cx43 time course may be due to
different injury models or different age, highlighting the
importance of treating jTBI as a different pathology than
adult TBI (Giza et al., 2007). Thus, it is likely that the
determining factor of whether connexin under- or over-
expression is beneficial or detrimental is determined by
the injury type and the time point after injury, similar to
what has been hypothesized for AQP4 where inhibition
of AQP4 would be beneficial during the edema formation
phase but not during the edema resolution phase
(Fukuda et al., 2012, 2013).
We hypothesized that astrocytes most likely play a
multifaceted role in the edema process. Initially, AQP4
permits water entry into the brain across the BBB.
Second, the astrocyte network of gap junction channels
allows the spread of water accumulation from the prima-
ry injured astrocytes to surrounding glia, causing them to
swell as well (Figure 1(A)). Furthermore, non-gap junc-
tion forming hemichannels may have an additional effect
in the post-injury cascade via excitotoxicity through
extracellular ATP and glutamate signaling (Bennett
et al., 2012; Kar et al., 2012). Because the changes in
Cx43 expression after jTBI followed AQP4 expression
changes, we hypothesized that Cx43 is the main gap junc-
tion protein involved in the spread of edema. We tested
this hypothesis to examine if decreasing Cx43 after jTBI
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would result in decreased edema, leading to improved
recovery using siCx43.
The Effect of siCx43 Injection After jTBI
Injection of siCx43 resulted in improved motor function
after jTBI with siCx43-treated animals having fewer foot
faults than siGLO-treated animals (Figure 4(A)).
However, even though siCx43 animals spent more time
on the rotarod than siGLO animals, this difference was
not significant (Figure 4(B)). We cannot explain the
reason for this discrepancy between the motor function
tests, but our results are in line with previous studies
where the foot-fault test had better discrimination
between groups compared with the rotarod test (Ajao
et al., 2012; Kamper et al., 2013). We observed a decrease
in GFAP immunoreactivity after siCx43 injection after
jTBI (Figure 6). This decrease in GFAP is in accordance
with an adult TBI study using antisense oligonucleotide
pretreatment against Cx43 (Wu et al., 2013) and another
study in which gap junction inhibitors, carbenoxolone
and octanol, were administered in adult rats that under-
went a stab wound to mimic brain injury (Andersson
et al., 2011). Although the exact function and implication
of changes in GFAP immunoreactivity is debated, it is
commonly regarded to be associated with astrogliosis
(Sofroniew, 2005; Sofroniew and Vinters, 2010). Some
evidence suggests that reactive astrogliosis may contrib-
ute to worsened secondary injury depending on the time
point and injury model (Laird et al., 2008).
To study edema after jTBI, we used MRI. DWI and
T2WI imaging are routinely used clinically as a measure
of edema (Galloway et al., 2008; Chastain et al., 2009)
and in animal models, including juvenile animals (Badaut
et al., 2011; Fukuda et al., 2012, 2013). We used these
clinically relevant imaging modalities to map the time
course of evolution of edema. ADC is a DWI parameter
that measures water mobility, and T2 is a measure of
water content. In a previous study using siAQP4, both
ADC and T2 were decreased in jTBI animals injected
with siAQP4, signifying decreased edema, which was
associated with improved behavioral outcomes and
decreased reactive astrogliosis (Fukuda et al., 2013).
Thus, we hypothesized that the inhibition of edema and
suppression of secondary injury spread by limiting water
diffusion through the astrocyte network could be
achieved by either blocking water channels (AQP4,
astrocyte-BBB) or gap junctions (connexins, astrocyte–
astrocyte communication). However, contrary to our ini-
tial hypothesis, postinjury administration of siCx43 did
not result in a significant decrease in edema or BBB dis-
ruption (Figure 6).
There are several possible explanations for these
observations. First, it is possible that both Cx43 and
Cx30 must be knocked down to decrease edema.
Indeed, it is very plausible that water may still be prop-
agated across the astrocyte network from the primary
injury site to secondary injury sites through Cx30, com-
pensating for the downregulated Cx43 channels. It would
be interesting to see the effect of double knockdown
treatment for Cx43/Cx30 in future studies; however, the
siRNA approach is not the best to achieve this because it
is very challenging to have a double knockdown in the
same cells. However, it is also important to note that
combination therapies do not always have benefit over
monotherapies. In fact, a recent review showed that out
of six combination treatments for TBI, only two showed
modest improvements over monotherapy, with some
showing decrease of efficacy over monotreatments
(Margulies et al., 2016). Second, pretreatment/precondi-
tioning with a gap junction inhibitor found a greater
difference between the control group and the treated
group than posttreatment (Perez Velazquez et al.,
2006; Andersson et al., 2011). This antisense-
oligodeoxynucleotide against Cx43 treatment may have
resulted in decreased edema due to the pre-injury injec-
tion of the drug. Third, Cx43 in juvenile animals may not
be a key player in the edema process. Water propagation
or clearance could be a function that is more central to
other astrocytic proteins, namely AQP4 (Badaut et al.,
2011). Recent results showed that the injection of siCx43
does not modify ADC in contrast to injection of siAQP4
(Jullienne et al., 2018). Altogether, these results continue
to support the hypothesis that AQP4 is the main contrib-
utor in edema formation/resolution after jTBI. However,
it is possible that variations in the alternates suggested
earlier may also contribute. Indeed, astrocytic Cx43 and
Cx30 conditional double knockout mice have a leaky
BBB and astrocyte endfeet swelling (Ezan et al., 2012).
Further, in a sheep model of global ischemia, Cx43 inhi-
bition through a specific mimetic peptide was shown to
result in increased neuronal and oligodendrocyte cell
count if the peptide was given after the ischemia but
not before and during ischemia (Davidson et al., 2013).
Although TBI studies on astrocytic Cx43 are sparse,
increased Cx43 has been associated with other brain
pathologies (Chew et al., 2010). Ischemic stroke studies
have reported beneficial results by specific inhibition of
Cx43 in in vitro models (Chew et al., 2010) and general
gap junction inhibition in vivo (Perez Velazquez et al.,
2006; Andersson et al., 2011). Thus, siCx43 may be a
unique and useful new technical approach to study
in vivo the involvement of Cx43 as well as a potential
therapeutic tool in other brain injury models as well.
However, it is interesting to note that in models of cere-
bral hemorrhage, general gap junction inhibitors such as
carbenoxolone and octanol have elicited detrimental
effects, more specifically in a model of intracerebral hem-
orrhage (Manaenko et al., 2009) and experimental sub-
arachnoid hemorrhage (Ayer et al., 2010). As proposed
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by these authors, brain hemorrhage may follow a differ-
ent path than TBI and stroke—namely that the injurious
factors are extracellular, and the intra-astrocellular brid-
ges formed by gap junctions may not be as important
(Ayer et al., 2010).
Limitations of the Study
Our current work has several limitations: (a) We previ-
ously observed significant improvement using siAQP4
cortical injections after jTBI with improvement in
motor function at 3 days, decreased BBB permeability,
astrogliosis, and neuronal cell death (Fukuda et al.,
2013), even with approximately 25% decrease in AQP4
protein expression (Badaut et al., 2011; Fukuda et al.,
2013). The degree of Cx43 expression was similar with
a 19% decrease after siCx43 injection, but the benefits of
the treatment were limited relative to siAQP4 treatment.
However, we cannot exclude the possibility that larger
decreases in Cx43 expression might have an effect on
edema formation and change the outcome after treat-
ment, which would be interesting to address in future
studies. (b) We focused only on targeting Cx43 in the
present study based on our previous studies examining
the effects of siAQP4 on Cx43 expression (Jullienne et al.,
2018). However, the role of Cx30 in edema and astroglio-
sis after jTBI cannot be ruled out.
Conclusion
In conclusion, we show here for the first time the tempo-
ral changes in Cx43 and GFAP expression after jTBI. We
also show that siCx43 injection after injury in juvenile
animals results in improved sensorimotor behavioral
recovery, associated with decreased Cx43 and reactive
astrogliosis but is not associated with changes in edema
formation. Future studies could further examine the
mechanistic pathways underlying the beneficiary effects
such as decreased cell death, neuroinflammation, or
decreased excitotoxicity.
Summary
Blocking the temporal changes in Cx43 expression using
siRNA improves sensorimotor recovery associated with
decrease in reactive astrocytes after jTBI.
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